Enalees, a French pioneer in rapid PCR tests for animal health, has launched Rhéa, its new range of rapid molecular diagnostic tests for cattle, sheep and goats.
This innovation marks a strategic step in terms of R&D development for Enalees, following its international rollout of two ranges of tests – one for horses and the other for cats and dogs.
The Rhéa range addresses a growing need in the sector: enabling veterinarians to act quickly and accurately in the field, even in the most remote areas, by diagnosing, then treating, ruminants on site, without the need for a laboratory. The first panel test available, Rhéa Vector-Borne Diseases, simultaneously detects four major pathogens in under 40 minutes, directly in the field: Theileria spp., Babesia spp., Anaplasma spp. (including A. marginale and A. phagocytophilum), and Borrelia spp. These pathogens can also be detected in a monovalent format. Together, these four pathogens can seriously affect the health and productivity of animals.
"Rhéa is a powerful symbol of our commitment; bringing innovation to field veterinarians using simple, reliable tools tailored to the demands of rural veterinary medicine,” said Laurent Thiery, president and co-founder of Enalees.
The expansion of Enalees’ rapid test range to include the livestock sector opens up a market three times larger than that of the pet sector, offering targeted solutions for cattle, poultry, pigs, sheep and goats.
This innovation strategy has been made possible by the €15 million fundraising round completed in 2024, as well as support from the public France 2030 initiative – the Première Usine (First Factory) program - through which Enalees received a non-dilutive grant of €2.7 million in 2025 to build its first production plant in France.
The Rhéa range of tests will be available from June 2025.